Drugs / AZD0120
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07350837 | Jan → Dec 2026 expected | anti-HLA hyperimmunization | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07295847 | Jan 2026 → Feb 2028 expected | idiopathic inflammatory myopathy, rheumatoid arthritis, systemic sclerosis | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07224373 | Dec 2025 → Dec 2028 expected | multiple sclerosis | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07073547 | Jul 2025 → May 2028 expected | plasma cell myeloma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07081646 | Aug 2025 → Aug 2029 expected | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06897930 | Apr 2025 → May 2029 expected | systemic lupus erythematosus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05850234 | Jul 2023 → Aug 2027 expected | refractory plasma cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07391657 | Feb 2026 → Jun 2028 expected | refractory plasma cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-26 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma gracellbio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07081646 ↗ |
| Known as | GC012F | “A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or...” NCT07081646 ↗1“AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor-T Cell (CAR-T) Therapy” NCT07350837 ↗ |
| Modality | Cell therapy | “AZD0120, a CD19/BCMA dual CAR T-cell therapy” NCT05850234 ↗ |
| Route | Other | “Single infusion of AZD0120” NCT06897930 ↗ |
| Target | CD19 | “AZD0120, a CD19/BCMA dual CAR T-cell therapy” NCT05850234 ↗ |